Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: ect. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2021-004987-91 Sponsor Protocol Number: 2020/ABM/01/00098 Start Date*: 2021-11-17
    Sponsor Name:Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
    Full Title: Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation (IRE-CaCl2, ECT and IRE) on quality of life and progression – free survival in patients with pancreatic can...
    Medical condition: Unresectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003589-15 Sponsor Protocol Number: ECT-HN Start Date*: 2019-01-24
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial
    Medical condition: carcinoma of the oral cavity and oropharynx
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005111-24 Sponsor Protocol Number: 3 Start Date*: 2006-01-16
    Sponsor Name:Dept. of Anaesthesia and Intensive Care, Haukeland University Hospital
    Full Title: Fluid therapy to patients reciving therapeutic hypothermia after cardiac arrest
    Medical condition: The study is carried out on patients at our Hospital, being treated with therapeutic hypothermia after cardiac arrest. The aim of the study is to tell if standard fluid therapy (RingerAC) leads to...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002177-37 Sponsor Protocol Number: 1321.7 Start Date*: 2016-06-01
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: Single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilat...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10066899 Venous thromboembolism LLT
    18.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) CZ (Completed) IT (Completed) DE (Completed) Outside EU/EEA GR (Completed) HU (Completed) BE (Completed) ES (Prematurely Ended) BG (Completed) AT (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000730-42 Sponsor Protocol Number: ARG-E07 Start Date*: 2009-01-09
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrom...
    Medical condition: Heparin induced thrombocytopenia (HIT) Type II
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048672 Heparin-induced thrombocytopenia type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006333-19 Sponsor Protocol Number: M2021001 Start Date*: 2022-05-12
    Sponsor Name:Amsterdam UMC
    Full Title: EMECLO: the Electroconvulsive therapy vs. MEdication in patients with CLOzapine-refractory symptoms trial
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001715-21 Sponsor Protocol Number: S59102 Start Date*: 2016-09-09
    Sponsor Name:UZ Leuven
    Full Title: Intravenous ketamine for Treatment Resistant Depression: Exploring biomarkers of response and relapse A double-blind, randomized controlled trial
    Medical condition: Major depressive disorder and Bipolar Disorder I and II
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005195 10037180 Psychiatric symptoms NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002451-26 Sponsor Protocol Number: 538264464328 Start Date*: 2015-05-15
    Sponsor Name:Department of Psychiatry, Helsinki University Central Hospital
    Full Title: The effect of intranasal ketamine on suicidality in severely depressed and suicidal patients. Randomized, placebo-controlled study
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018723-26 Sponsor Protocol Number: 1160.86 Start Date*: 2010-07-15
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: An open label, non-comparative, pharmacokinetic and pharmacodynamic study to evaluate the effect of Dabigatran Etexilate on coagulation parameters including a calibrated thrombin time test in patie...
    Medical condition: Primary VTE prevention in patients with moderate renal impairment (Creatinine Clearance 30-50 ml/min) following total hip or knee replacement surgery
    Disease: Version SOC Term Classification Code Term Level
    12.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-004813-41 Sponsor Protocol Number: 1321.3 Start Date*: 2014-05-26
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ...
    Medical condition: Hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10019524 Hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PT (Completed) SE (Completed) ES (Completed) FI (Completed) EE (Completed) LV (Prematurely Ended) CZ (Completed) IT (Completed) SK (Completed) NL (Completed) BE (Completed) AT (Completed) NO (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006866-27 Sponsor Protocol Number: 1160.88 Start Date*: 2012-03-15
    Sponsor Name:Boehringer Ingelheim (Canada) Ltd./Ltée
    Full Title: Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years
    Medical condition: Venous Thrombotic Event
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10066899 Venous thromboembolism LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003251-13 Sponsor Protocol Number: D1449L00002 Start Date*: 2005-10-20
    Sponsor Name:AstraZeneca UK Ltd
    Full Title: Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot Study
    Medical condition: Depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013455-30 Sponsor Protocol Number: AOBS-ECT-CH Start Date*: 2009-12-15
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: EFFICACY OF ELETTROPORATION COMBINED WITH BLEOMYCIN IN THE TREATMENT OF KELOIDS AND HYPERTROPHIC SCARS: A PILOT STUDY
    Medical condition: KELOIDS AND HYPERTROPHIC SCARS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040785 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003886-15 Sponsor Protocol Number: TELIT L 01747 Start Date*: 2006-09-12
    Sponsor Name:SANOFI-AVENTIS S.P.A
    Full Title: Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dos...
    Medical condition: Acute exacerbation of chronic-obstructive pulmonary disease.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029978 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002114-12 Sponsor Protocol Number: 1160.106 Start Date*: 2013-09-20
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: Open-label, randomized, parallel-group, active-controlled, multi-centre, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10066899 Venous thromboembolism LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) BE (Completed) ES (Completed) SE (Completed) FI (Completed) SK (Completed) GR (Completed) NO (Completed) IT (Completed) AT (Completed) BG (Completed) Outside EU/EEA FR (Completed) HU (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001722-27 Sponsor Protocol Number: D1250C00042 Start Date*: 2007-10-11
    Sponsor Name:AstraZeneca AB
    Full Title: Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to Vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk f...
    Medical condition: Paroxysmal persistent or permanent non-valvular atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001520-37 Sponsor Protocol Number: KETECT Start Date*: 2014-02-14
    Sponsor Name:Skåne University Hospital, Malmö
    Full Title: Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder
    Medical condition: Major depression disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10019063 Hallucination PT
    18.0 10015919 - Eye disorders 10013036 Diplopia PT
    18.0 100000004863 10061243 Post procedural nausea LLT
    18.0 10029205 - Nervous system disorders 10047343 Vertigo CNS origin PT
    18.0 10037175 - Psychiatric disorders 10015533 Euphoria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002954-21 Sponsor Protocol Number: KETIVEDI2001 Start Date*: 2013-05-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An exploratory, blinded, randomized, placebo-controlled study in subjects with depressive disorder to investigate the effect of minocycline on relapse after successful intravenous ketamine/minocycl...
    Medical condition: Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10004940 Bipolar II disorder PT
    16.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000583-18 Sponsor Protocol Number: 1160.108 Start Date*: 2014-07-25
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years
    Medical condition: Secondary prevention of venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FI (Completed) AT (Completed) GR (Completed) IT (Completed) LT (Completed) CZ (Completed) BE (Completed) SK (Completed) SE (Temporarily Halted) BG (Completed) FR (Completed) HU (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001240-61 Sponsor Protocol Number: allo-APZ2-ACLF-II-01 Start Date*: 2018-12-19
    Sponsor Name:RHEACELL GmbH & Co. KG
    Full Title: An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF)
    Medical condition: Acute-on-Chronic Liver Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10077305 Acute on chronic liver failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 04:53:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA